En Es
Categories

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological functions. The company also provides sequencing and array-based solutions for genetic analysis, as well as genotyping, NIPT and whole-genome sequencing services for government laboratories, hospitals, an ...
Products Covid-19NewsSummary
Close

Covid-19 Illumina

Clinical Laboratory

SARS-CoV-2 NGS Test
Illumina COVIDSeq Test

The Illumina COVIDSeq Test is a high-throughput, next-generation sequencing test is intended for the detection of SARS-CoV-2 virus RNA in authorized countries and virus genome analysis for research use. This amplicon-based NGS test includes 2019-nCoV primers designed to detect RNA from the SARS-CoV-2 virus in nasopharyngeal, oropharyngeal, and mid-turbinate nasal swabs from patients with signs and symptoms of infection who are suspected of COVID-19.
More details

SARS-CoV-2 (COVID-19) Test
Illumina COVIDSeq Test

The Illumina COVIDSeq Test is the first NGS test approved for use under the US Food and Drug Administration’s Emergency Use Authorization (EUA). This amplicon-based NGS test includes 2019-nCoV primers designed to detect RNA from the SARS-CoV-2 virus in nasopharyngeal, oropharyngeal, and mid-turbinate nasal swabs from patients with signs and symptoms of infection who are suspected of COVID-19. The test can be run on the Illumina NovaSeq 6000 Sequencing System, NextSeq 500 Sequencing System, NextSeq 550 Sequencing System, or NextSeq 550Dx Instrument.
More details
Close

News of Illumina

Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test

20 Aug 2021
Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test
Illumina, Inc. (San Diego, CA, USA) has acquired GRAIL (Menlo Park, CA, USA), a healthcare company focused on life-saving early detection of multiple cancers.
Read More
Close

About Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological functions. The company also provides sequencing and array-based solutions for genetic analysis, as well as genotyping, NIPT and whole-genome sequencing services for government laboratories, hospitals, and reference laboratories, among others.
FaceBook Twitter Google+ Linked in
SARS-CoV-2 (COVID-19) Test

SARS-CoV-2 (COVID-19) Test

Model: Illumina COVIDSeq Test
Request Information

Description:

The Illumina COVIDSeq Test is the first NGS test approved for use under the US Food and Drug Administration’s Emergency Use Authorization (EUA). This amplicon-based NGS test includes 2019-nCoV primers designed to detect RNA from the SARS-CoV-2 virus in nasopharyngeal, oropharyngeal, and mid-turbinate nasal swabs from patients with signs and symptoms of infection who are suspected of COVID-19.
Read More

Full Description Features

Description

The Illumina COVIDSeq Test is the first NGS test approved for use under the US Food and Drug Administration’s Emergency Use Authorization (EUA). This amplicon-based NGS test includes 2019-nCoV primers designed to detect RNA from the SARS-CoV-2 virus in nasopharyngeal, oropharyngeal, and mid-turbinate nasal swabs from patients with signs and symptoms of infection who are suspected of COVID-19. The test can be run on the Illumina NovaSeq 6000 Sequencing System, NextSeq 500 Sequencing System, NextSeq 550 Sequencing System, or NextSeq 550Dx Instrument. Request Information

Features

•Accuracy: Detects 98 targets on SARS-CoV-2 for highly accurate detection

•Quality Control: Internal control consists of 11 human mRNA targets in every reaction

•Flexibility: Available on NovaSeq 6000 S4 and SP flow cells and on NextSeq 500/550/550Dx (in RUO mode) HO flow cell Request Information

Send A Message To This Supplier

* Required Information
* Email
To
Illumina (SARS-CoV-2 (COVID-19) Test)
* Message

Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions